Colitis – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Colitis – Pipeline Review, H2 2018’, provides an overview of the Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Colitis

– The report reviews pipeline therapeutics for Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Colitis therapeutics and enlists all their major and minor projects

– The report assesses Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Colitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Colitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akebia Therapeutics Inc

Apollo Endosurgery Inc

Bristol-Myers Squibb Co

Concenter BioPharma Silkim Ltd

Cosmo Pharmaceuticals NV

Dr. Falk Pharma GmbH

EA Pharma Co Ltd

Genfit SA

Immuron Ltd

Inflazome Ltd

Ogeda SA

Pfizer Inc

RDD Pharma Ltd

Saniona AB

Soligenix Inc

Sublimity Therapeutics Ltd

Vitality Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Colitis Overview

Colitis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Colitis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Colitis Companies Involved in Therapeutics Development

Akebia Therapeutics Inc

Apollo Endosurgery Inc

Bristol-Myers Squibb Co

Concenter BioPharma Silkim Ltd

Cosmo Pharmaceuticals NV

Dr. Falk Pharma GmbH

EA Pharma Co Ltd

Genfit SA

Immuron Ltd

Inflazome Ltd

Ogeda SA

Pfizer Inc

RDD Pharma Ltd

Saniona AB

Soligenix Inc

Sublimity Therapeutics Ltd

Vitality Biopharma Inc

Colitis Drug Profiles

AcTMP-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKB-6899 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-346 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APY-0201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BC-1215 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986104 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budesonide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSA-13 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyloxalylglycine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dusquetide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elafibranor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ESN-601 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate PD-L1 for Colitis and Graft Versus Host Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GFC-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-124E Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAK-11049 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCC-950 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit LTC4 for Colitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit NFkB for Colitis and Enteritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06425090 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDD-2007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifamycin CR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-182 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Colitis and Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Colitis and Crohn's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYMB-104 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPC-1022 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-303 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Colitis Dormant Projects

Colitis Discontinued Products

Colitis Product Development Milestones

Featured News & Press Releases

May 10, 2018: Vitality's GI-targeted VBX-100 THC compound to be investigated as treatment of recurrent difficile infections

May 07, 2018: Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program

Feb 05, 2018: Tillotts Pharma announces MHRA approval of Entocort Capsules for Microscopic Colitis

Feb 05, 2018: Tillotts Pharma announces MHRA approval of Entocort Capsules for Microscopic Colitis

Jul 19, 2017: Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease

Apr 18, 2017: Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies

Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Colitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Colitis Pipeline by Akebia Therapeutics Inc, H2 2018

Colitis Pipeline by Apollo Endosurgery Inc, H2 2018

Colitis Pipeline by Bristol-Myers Squibb Co, H2 2018

Colitis Pipeline by Concenter BioPharma Silkim Ltd, H2 2018

Colitis Pipeline by Cosmo Pharmaceuticals NV, H2 2018

Colitis Pipeline by Dr. Falk Pharma GmbH, H2 2018

Colitis Pipeline by EA Pharma Co Ltd, H2 2018

Colitis Pipeline by Genfit SA, H2 2018

Colitis Pipeline by Immuron Ltd, H2 2018

Colitis Pipeline by Inflazome Ltd, H2 2018

Colitis Pipeline by Ogeda SA, H2 2018

Colitis Pipeline by Pfizer Inc, H2 2018

Colitis Pipeline by RDD Pharma Ltd, H2 2018

Colitis Pipeline by Saniona AB, H2 2018

Colitis Pipeline by Soligenix Inc, H2 2018

Colitis Pipeline by Sublimity Therapeutics Ltd, H2 2018

Colitis Pipeline by Vitality Biopharma Inc, H2 2018

Colitis Dormant Projects, H2 2018

Colitis Dormant Projects, H2 2018 (Contd..1), H2 2018

Colitis Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Colitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports